# Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers

> **NCT07542262** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 128 (estimated)

## Conditions studied

- Colorectal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Low-dose nivolumab
- **DRUG:** Low-dose nivolumab with/without chemotherapy
- **DRUG:** Low-dose nivolumab combined with chemotherapy

## Key facts

- **NCT ID:** NCT07542262
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-06-03
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-03-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07542262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07542262, "Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07542262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*